.jpg "G1 Therapeutics Inc (NASDAQ: GTHX)")
Analysts have been eager to weigh in on the Healthcare sector with new ratings on G1 Therapeutics Inc (NASDAQ: GTHX) and Medtronic (NYSE: MDT).
G1 Therapeutics Inc (NASDAQ: GTHX)
In a report issued on May 24, Dane Leone from BTIG assigned a Buy rating to G1 Therapeutics Inc (NASDAQ: GTHX), with a price target of $60. The company’s shares closed on Friday at $50.06, close to its 52-week high of $52.76.
Leone wrote:
“ASCO Based Upon Abstract & Mgmt Discussions We are raising our Price Target for GTHX to $60 from $48 previously, as we now include explicit forecasts for G1T38 (~$156m during 2023E). Our forecasts for G1T38 are currently a place-marker within the Cancer population who have experienced endocrine therapy (ET). We think full read-outs of the current dataset at ASCO and into 2019, along with the development timeline of G1T48, will significantly impact our outlook. We Remain Buy rated.”
According to TipRanks.com, Leone is a 5-star analyst with an average return of 21.3% and a 72.9% success rate. Leone covers the Healthcare sector, focusing on stocks such as Voyager Therapeutics Inc, Vertex Pharmaceuticals, and Blueprint Medicines.
Currently, the analyst consensus on G1 Therapeutics Inc is Strong Buy and the average price target is $60, representing a 19.9% upside.
In a report issued on May 18, Needham also reiterated a Buy rating on the stock with a $60 price target.
See today’s analyst top recommended stocks >>
Medtronic (NYSE: MDT)
BTIG analyst Sean Lavin assigned a Hold rating to Medtronic (NYSE: MDT) on May 24. The company’s shares closed on Friday at $86.30.
Lavin said:
“Targets At Analyst Day Will Be Key, In Our View Our key thoughts following the FQ4 print include: 1) a positive view on top- line given the consistent 7% c.c. revenue growth in the 2H after a disappointing 1H, 2) confidence in revenue guidance but caution around 50bps margin expansion in FY19, and 3) continued questions around the long-term drivers of the business. Admittedly, we don’t have a strong sense heading into the June 5 th Analyst Day given the company’s mixed track record of meeting goals outlined in the meeting. It is possible that the recent management addition may lead to tighter messaging on the investor relations front (our guess is more conservatism). Shares have enjoyed a nice run over the last month, narrowing the valuation gap between MDT and its large peers.”
According to TipRanks.com, Lavin is a 5-star analyst with an average return of 15.4% and a 63.1% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Helius Medical Technologies, Tactile Systems Technology, and Obalon Therapeutics Inc.
Medtronic has an analyst consensus of Strong Buy, with a price target consensus of $96.60.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
